突变型p53作为癌症治疗靶点
TP53是人类癌症中最常发生改变的基因,在约50%的浸润性肿瘤中存在突变,而在高级别浆液性卵巢癌、三阴性乳腺癌、食管癌、小细胞肺癌和鳞状细胞肺癌等难治性癌症中,p53突变率至少为80%。尽管传统上认为突变型p53难以成药,但已有多种化合物(如PRIMA-1、APR-246、PK11007、PK7088、ZMC1、COTI-2及特定肽类)被报道可将突变型p53重新激活为具有野生型特性的形式,并在表达突变型p53的临床前模型中显示出抗癌活性。目前APR-246和COTI-2已进入临床试验:APR-246的I/IIa期试验未报告主要不良效应,正在晚期浆液性卵巢癌患者中进行Ib/II期试验;COTI-2正在晚期妇科癌症患者中进行I期试验。然而,任何突变型p53重新激活化合物对人体癌症是否有效仍有待证实。
要点
- TP53是最常突变的基因,在约50%浸润性肿瘤中突变,在高级别浆液性卵巢癌等难治癌症中突变率至少80%。
- 多种化合物(PRIMA-1、APR-246、PK11007、PK7088、ZMC1、COTI-2及肽类)可将突变型p53重新激活为野生型特性。
- APR-246和COTI-2已进入临床试验,但突变型p53重新激活化合物对人癌症的疗效仍有待证实。
核心结论
- 突变型p53蛋白是开发新型抗癌治疗的重要候选靶点,但任何突变型p53重新激活化合物对人体癌症是否有效仍有待证实。
研究设计与样本
- 本文为综述,检索范围未在原文中报告。
主要发现
- TP53在约50%的浸润性肿瘤中突变,在高级别浆液性卵巢癌、三阴性乳腺癌、食管癌、小细胞肺癌和鳞状细胞肺癌中至少80%的样本存在p53突变。
- PRIMA-1、APR-246、PK11007、PK7088、ZMC1、COTI-2及特定肽类被报道可将突变型p53重新激活为具有野生型特性的形式。
- 这些化合物在表达突变型p53的临床前模型中显示出抗癌活性。
- APR-246的I/IIa期临床试验未报告主要不良效应;APR-246正在晚期浆液性卵巢癌患者中进行Ib/II期试验,COTI-2正在晚期妇科癌症患者中进行I期试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 任何突变型p53重新激活化合物对人体癌症是否有效仍有待证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TP53 (p53) is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumours. However, in some of the most difficult-to-treat cancers such as high-grade serous ovarian cancers, triple-negative breast cancers, oesophageal cancers, small-cell lung cancers and squamous cell lung cancers, p53 is mutated in at least 80% of samples. Clearly, therefore, mutant p53 protein is an important candidate target against which new anticancer treatments could be developed. Although traditionally regarded as undruggable, several compounds such as p53 reactivation and induction of massive apoptosis-1 (PRIMA-1), a methylated derivative and structural analogue of PRIMA-1, i.e. APR-246, 2-sulfonylpyrimidines such as PK11007, pyrazoles such as PK7088, zinc metallochaperone-1 (ZMC1), a third generation thiosemicarbazone developed by Critical Outcome Techonologies Inc. (COTI-2) as well as specific peptides have recently been reported to reactive mutant p53 protein by converting it to a form exhibiting wild-type properties. Consistent with the reactivation of mutant p53, these compounds have been shown to exhibit anticancer activity in preclinical models expressing mutant p53. To date, two of these compounds, i.e. APR-246 and COTI-2 have progressed to clinical trials. A phase I/IIa clinical trial with APR-246 reported no major adverse effect. Currently, APR-246 is undergoing a phase Ib/II trial in patients with advanced serous ovarian cancer, while COTI-2 is being evaluated in a phase I trial in patients with advanced gynaecological cancers. It remains to be shown however, whether any mutant p53 reactivating compound has efficacy for the treatment of human cancer.
引用
- Duffy MJ, Synnott NC, Crown J, et al. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017. PMID: 28756138. doi:10.1016/j.ejca.2017.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。